What scientific journals can you not be bothered to keep up with? I know, sometimes it's tempting to answer "all of them", but a well-informed chemist really should watch what comes out in the better ones. But how about the not-so-better...Show More Summary
I’m taking a break from blogging this week and rerunning some of 2014's popular posts. Click here to see the original post and comments from May 2014. Last week, I attended the bigger-than-ever Armada Healthcare Specialty Pharmacy Summit...Show More Summary
There have been several analyses that have suggested that phenotypic drug discovery was unusually effective in delivering "first in class" drugs. Now comes a reworking of that question, and these authors (Jörg Eder, Richard Sedrani,Show More Summary
I’m taking a break from blogging this week and rerunning some of 2014's popular posts. Click here to see the original post and comments from February 2014. As predicted, McKesson and Rite Aid announced a new generic purchasing agreement. Show More Summary
Mentioning such a small compound as pirfenidone prompts me to put up the graphic shown below: these are the smallest commonly used drugs that I can think of. (OK, there's cocaine as a nasal anaesthetic - no, really - but that's where I draw the line at "commonly used". Show More Summary
Experimental and Clinical Cardiology used to be a reputable journal. Now it's a trash heap piled with crap. No, literally - the Ottawa Citizen newspaper has proof, thanks to reporter Tom Spears (who's an experienced hand at this). The...Show More Summary
It has been a bizarre ride for InterMune, its employees, and its investors. But now it ends with Roche buying them for $8.3 billion dollars, a sum that would have brought incredulous stares a few years ago. The deal makes sense for Roche, and it will provide investors a rationale for years as they buy into small biopharma companies - trying to pick the next InterMune, you know.
According to the 2014 U.S. Mobile App Report by Comscore, U.S. digital consumers now spend more time using mobile apps than they do on desktop computers (see chart below). "Total U.S. digital media time spent has jumped 24 percent in...Show More Summary
Specialty Pharmacy and Distribution NetworksOctober 28-29, 2014 | Philadelphia, PAwww.cbinet.com/specialtydistribution Now in its fifth year, the Specialty Pharmacy Distribution Networks Conference uniquely addresses the complexity of commercialization and market access of specialty products. Show More Summary
For the past few years here in Washington, the summer ended in August seemingly with the flip of a switch following Labor Day Weekend. The daily threat of storms abated, the high humidity retreated, air conditioners were switched off in … Continue reading ?
Science has an article on palbociclib, the Pfizer CDK4 compound that came up here the other day when we were discussing their oncology portfolio. You can read up on the details of how the compound was put in the fridge for several years, only to finally emerge as one of the company's better prospects. Show More Summary
So here's a question for the medicinal chemists: how come we don't like bromoaromatics so much? I know I don't, but I have trouble putting my finger on just why. I know that there's a ligand efficiency argument to be made against them - all that weight, for one atom - but there are times when a bromine seems to be just the thing. Show More Summary
Edward Zartler ("Teddy Z" of the Practical Fragments blog) has a short piece in the latest ACS Medicinal Chemistry Letters on fragment-based drug discovery. He applies the term "fragonomics" to the field (more on this in a moment), and...Show More Summary
FDA’s OPDP views nearly all industry communication – whatever the venue and intent – through a lens of advertising. Certainly a big focus of regulatory enforcement has been direct-to-consumer advertising and for a long time, there has been guidance available … Continue reading ?
Perseverance is a critical variable in drug discovery. Too little of it, and you are absolutely guaranteed to fail - no drug has ever made it to market without trying the patience of everyone involved. Too much of it, and you are very...Show More Summary
John LaMattina has a look at Pfizer's oncology portfolio, and what their relentless budget-cutting has been doing to it. The company is taking some criticism for having outlicensed two compounds (tremelimumab to AstraZeneca and neratinib to Puma) which seem to be performing very well after Pfizer ditched them. Show More Summary
Wow, hard to believe that summer is almost over. Pack up the beach chairs, send the kids back to school, and enjoy this curated collection of curiosities, combed from the Drug Channels beach. In this issue: Walgreen's Billion-DollarShow More Summary